SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)
$20.45 -0.07 (-0.3411%)
Analysed SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) News Sources
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
08-09-2026
proactiveinvestors.com
Sarepta Therapeutics Q2 Earnings Call Highlights
06-08-2026
marketbeat.com
Sarepta Therapeutics Inc (SRPT) (Q2 2026) Earnings Call Highlights: Strong Profitability and ...
06-08-2026
yahoo.com
Sarepta Faces Competitive Pressures Despite Pipeline Updates, RBC Says
06-08-2026
yahoo.com
Sarepta (SRPT) Q2 2026 Earnings Call Transcript
13-08-2026
fool.com
Sarepta (SRPT) Stock Looks Fully Valued As Sales Trail Fair Value
25-08-2026
yahoo.com
SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’
27-08-2026
stocktwits.com
Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
31-08-2026
yahoo.com
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
04-09-2026
yahoo.com
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
08-09-2026
yahoo.com
What is the current price of SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)?
The current price of SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) is $20.45.
SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) absolute price change since previous trading day?
The absolute price change of SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) since the previous trading day is $-0.07.
SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) percentage price change since previous trading day?
The percentage price change of SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) since the previous trading day is -0.3411%.
What is the most recent average sentiment score for SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)?
The most recent average sentiment score for SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) is 67 out of 100.
What is the most recent average sentiment for SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)?
The most recent sentiment for SAREPTA THERAPEUTICS INC (SRPT:NASDAQ) is .
SEC-8K** Filing Available For SAREPTA THERAPEUTICS INC (SRPT:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.